Krystal Biotech (KRYS) EBIT Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 12.69% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 75.16% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -347.04% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 80.62% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 1.27% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 8.65% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1,386.07% |
| 10 | Krystal Biotech | 9.05 Bn | 8.23 Bn | 110.03 Mn | 48.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.10% |
| Dec 31, 2025 | 7.00% |
| Sep 30, 2025 | 84.11% |
| Jun 30, 2025 | 358.87% |
| Mar 31, 2025 | 642.37% |
| Dec 31, 2024 | 1,173.86% |
| Sep 30, 2024 | 186.45% |
| Jun 30, 2024 | 122.51% |
| Mar 31, 2024 | 86.31% |
| Dec 31, 2023 | 109.34% |
| Sep 30, 2023 | 17.35% |
| Jun 30, 2023 | -32.33% |
| Mar 31, 2023 | 2.79% |
| Dec 31, 2022 | -58.95% |
| Sep 30, 2022 | -100.94% |
| Jun 30, 2022 | -75.40% |
| Mar 31, 2022 | -249.91% |
| Dec 31, 2021 | -109.94% |
| Sep 30, 2021 | -61.69% |
| Jun 30, 2021 | -135.73% |
| Mar 31, 2021 | -141.39% |
| Dec 31, 2020 | -69.32% |
| Sep 30, 2020 | -81.21% |
| Jun 30, 2020 | -18.06% |
| Mar 31, 2020 | -26.67% |
| Dec 31, 2019 | -45.86% |
| Sep 30, 2019 | -79.74% |
| Jun 30, 2019 | -140.51% |
| Mar 31, 2019 | -106.15% |
| Dec 31, 2018 | -181.64% |
| Sep 30, 2018 | -42.00% |
| Jun 30, 2018 | -242.52% |
| Mar 31, 2018 | -389.68% |
| Dec 31, 2017 | -141.61% |
| Sep 30, 2017 | -550.00% |